StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$0.92−0.06 (-6.39%)

Close on Nov 20, 2026Market cap $92.40MP/E –Yield –

Cellectis gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was $72.95M, up 75.8% from the year before. The highest annual figure on record is $72.95M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.95M+75.8%
FY2024Dec 31, 2024$41.51M+230483.3%
FY2023Dec 31, 2023$18.00K-99.9%
FY2022Dec 31, 2022$17.40M-39.0%
FY2021Dec 31, 2021$28.50M-42.0%
FY2020Dec 31, 2020$49.11M+1192.9%
FY2019Dec 31, 2019$3.80M-62.0%
FY2018Dec 31, 2018$9.99M-55.7%
FY2017Dec 31, 2017$22.57M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023$123.00K-63.5%
Q2 FY2022Jun 30, 2022$978.00K–
Q2 FY2021Jun 30, 2021-$578.00K–
Q2 FY2020Jun 30, 2020-$2.93M–
Q2 FY2019Jun 30, 2019$337.00K–

More Cellectis figures

See a number that looks wrong?